Rivaroxaban Krka 15 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban krka 15 mg filmomh. tabl.

krka d.d. novo mesto d.d. - rivaroxaban 15 mg - filmomhulde tablet - 15 mg - rivaroxaban 15 mg - rivaroxaban

Rivaroxaban Sandoz 15 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban sandoz 15 mg filmomh. tabl.

sandoz sa-nv - rivaroxaban 15 mg - filmomhulde tablet - 15 mg - rivaroxaban 15 mg - rivaroxaban

Rivaroxaban Sandoz GmbH 15 mg - 20 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban sandoz gmbh 15 mg - 20 mg filmomh. tabl.

sandoz gmbh - rivaroxaban 15 mg (rode tablet 15 mg); rivaroxaban 20 mg (bruin-rode tablet 20 mg) - filmomhulde tablet - 15 mg + 20 mg - rivaroxaban 15 mg; rivaroxaban 20 mg - rivaroxaban

Rivaroxaban Krka 2.5 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban krka 2.5 mg filmomh. tabl.

krka d.d. novo mesto d.d. - rivaroxaban 2,5 mg - filmomhulde tablet - 2,5 mg - rivaroxaban 2.5 mg - rivaroxaban

Rivaroxaban Aurobindo 15 mg + 20 mg, filmomhulde tabletten Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

rivaroxaban aurobindo 15 mg + 20 mg, filmomhulde tabletten

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - rivaroxaban 20 mg/stuk ; rivaroxaban 15 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171) - rivaroxaban

Rivaroxaban Sandoz 2.5 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban sandoz 2.5 mg filmomh. tabl.

sandoz sa-nv - rivaroxaban 2,5 mg - filmomhulde tablet - 2,5 mg - rivaroxaban 2.5 mg - rivaroxaban

Rivaroxaban Sandoz GmbH 2.5 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban sandoz gmbh 2.5 mg filmomh. tabl.

sandoz gmbh - rivaroxaban 2,5 mg - filmomhulde tablet - 2,5 mg - rivaroxaban 2.5 mg - rivaroxaban

Rivaroxaban EG 15 mg - 20 mg filmomh. tabl. Belġju - Olandiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rivaroxaban eg 15 mg - 20 mg filmomh. tabl.

eg sa-nv - rivaroxaban 15 mg (rode tablet (15 mg)); rivaroxaban 20 mg (bruinrode tablet (20 mg)) - filmomhulde tablet - rivaroxaban

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotische middelen - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Rivaroxaban Denk 15 mg, filmomhulde tabletten Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

rivaroxaban denk 15 mg, filmomhulde tabletten

denk pharma gmbh & co. kg prinzregentenstrasse 79 81675 mÜnchen (duitsland) - rivaroxaban 15 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; titaandioxide (e 171), - rivaroxaban